Skip to content

Trial Summary

This study is to capture and describe the patient and disease characteristics and the outcomes of adult patients with previously-treated advanced NSCLC who have been treated with Nivolumab

Acronym:

NIVO PAP

ACTRN/NCT /ethics:

NCT03804554

Scientific title:

Nivolumab in the Treatment of Patients With Non-small Cell Lung Cancer: The Australian Experience

Sponsor / Cooperative group:

Bristol-Myers Squibb

Trial & Patient Characteristics

Cancer TypeLung & mesothelioma
Trial TypeEarly detection, diagnosis, prognosis
PhaseAll phases
Age Range18 years and older
SexBoth
Tumour Stream Non-small Cell Lung Cancer
Cancer StageAll stages
Anticipated Start Date2018-10-03
Anticipated End Date2020-12-01

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorProfessor Michael Brown
Recruitment StatusRecruiting